Review Article| Volume 35, ISSUE 2, P313-331, June 2015

Antimicrobial Susceptibility Testing of Bacteria That Cause Gastroenteritis

Published:April 03, 2015DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zhang X.
        • McDaniel A.D.
        • Wolf L.E.
        • et al.
        Quinolone antibiotics induce shiga toxin-encoding bacteriophages, toxin production, and death in mice.
        J Infect Dis. 2000; 181: 664-670
        • Wong C.S.
        • Mooney J.C.
        • Brandt J.R.
        • et al.
        Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis.
        Clin Infect Dis. 2012; 55: 33-41
        • Guerrant R.L.
        • Van Gilder T.
        • Steiner T.S.
        • et al.
        Infectious Diseases Society of America. Practice guidelines for the management of infectious diarrhea.
        Clin Infect Dis. 2001; 32: 331-351
        • Clinical and Laboratory Standards Institute
        Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; Approved guideline - second edition. CLSI document M45-A2.
        Clinical and Laboratory Standards Institute, Wayne (PA)2010
        • Clinical and Laboratory Standards Institute
        Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement. M100 S24.
        Clinical and Laboratory Standards Institute, Wayne (PA)2014
        • DuPont H.L.
        Clinical practice. Bacterial diarrhea.
        N Engl J Med. 2009; 361: 1560-1569
        • Centers for Disease Control and Prevention
        Incidence and trends of infection with pathogens transmitted commonly through food – foodborne diseases active surveillance network, 10 U.S. sites, 1996-2012.
        MMWR. 2013; 62: 283-287
        • Ternhag A.
        • Asikainen T.
        • Giesecke J.
        • et al.
        A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species.
        Clin Infect Dis. 2007; 44: 696-700
        • Gilbert D.N.
        • Chambers H.F.
        • Eliopoulos G.M.
        • et al.
        The Sanford guide to antimicrobial therapy.
        44th edition. Antimicrobial Therapy, Inc, Sperryville (VA)2014
      1. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report. U.S. Department of Health and Human Services, CDC, Atlanta (GA)2012 (Available at:) (Accessed March 17, 2015)
        • Vlieghe E.R.
        • Jacobs J.A.
        • Van Esbroeck M.
        • et al.
        Trends of norfloxacin and erythromycin resistance of Campylobacter jejuni/Campylobacter coli isolates recovered from international travelers, 1994 to 2006.
        J Travel Med. 2008; 15: 419-425
        • Aarestrup F.M.
        • McDermott P.F.
        • Wegener H.C.
        Transmission of antibiotic resistance from food animals to humans.
        in: Nachamkin I. Szymanski C.M. Blaser M.J. Campylobacter. ASM Press, Washington, DC2008: 645-665
        • Bakeli G.
        • Sato K.
        • Kumita W.
        • et al.
        Antimicrobial susceptibility and mechanism of quinolone resistance in Campylobacter jejuni strains isolated from diarrheal patients in a hospital in Tokyo.
        J Infect Chemother. 2008; 14: 342-348
        • Engberg J.
        • Aarestrup F.M.
        • Taylor D.E.
        • et al.
        Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates.
        Emerg Infect Dis. 2001; 7: 24-34
        • Nelson J.M.
        • Chiller T.M.
        • Powers J.H.
        • et al.
        Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story.
        Clin Infect Dis. 2007; 44: 977-980
        • Griggs D.J.
        • Johnson M.M.
        • Frost J.A.
        • et al.
        Incidence and mechanism of ciprofloxacin resistance in Campylobacter spp. isolated from commercial poultry flocks in the United Kingdom before, during, and after fluoroquinolone treatment.
        Antimicrob Agents Chemother. 2005; 49: 699-707
        • Luo N.
        • Pereira S.
        • Sahin O.
        • et al.
        Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure.
        Proc Natl Acad Sci U S A. 2005; 102: 541-546
        • Wassenaar T.M.
        • Kist M.
        • de Jong A.
        Re-analysis of the risks attributed to ciprofloxacin-resistant Campylobacter jejuni infections.
        Int J Antimicrob Agents. 2007; 30: 195-201
        • McDermott P.F.
        • Bodeis S.M.
        • Aarestrup F.M.
        • et al.
        Development of a standardized susceptibility test for Campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem.
        Microb Drug Resist. 2004; 10: 124-131
        • Clinical and Laboratory Standards Institute
        Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; Approved standard - third edition. CLSI document M31-A3.
        Clinical and Laboratory Standards Institute, Wayne (PA)2008
      2. International Organization for Standardization (ISO) Standards. Clinical laboratory testing and in vitro diagnostic test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases (ISO 20776–1). Switzerland: ISO; 2006.

        • Gaudreau C.
        Disk diffusion method for erythromycin and ciprofloxacin susceptibility testing of Campylobacter jejuni and Campylobacter coli.
        J Clin Microbiol. 2013; 51: 380
        • Lehtopolku M.
        • Kotilainen P.
        • Puukka P.
        • et al.
        Inaccuracy of the disk diffusion method compared with the agar dilution method for susceptibility testing of Campylobacter spp.
        J Clin Microbiol. 2012; 50: 52-56
      3. European Committee on Antimicrobial Susceptibility Testing - EUCAST. Breakpoint tables for interpretation of MICs and zone diameters, Version 4.0. 2014. Available at: Accessed March 17, 2015.

      4. CLSI. Subcommittee of the Antimicrobial Susceptibility Testing, June 2014 meeting minutes. Available at: Accessed March 16, 2015.

        • Valdivieso-Garcia A.
        • Imgrund R.
        • Deckert A.
        • et al.
        Cost analysis and antimicrobial susceptibility testing comparing the E test and the agar dilution method in Campylobacter jejuni and Campylobacter coli.
        Diagn Microbiol Infect Dis. 2009; 65: 168-174
        • van der Beek M.T.
        • Claas E.C.
        • Mevius D.J.
        • et al.
        Inaccuracy of routine susceptibility tests for detection of erythromycin resistance of Campylobacter jejuni and Campylobacter coli.
        Clin Microbiol Infect. 2010; 16: 51-56
        • Jorgensen J.H.
        • Hindler J.F.
        New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria.
        Clin Infect Dis. 2007; 44: 280-286
        • Platts-Mills J.A.
        • Liu J.
        • Gratz J.
        • et al.
        Detection of Campylobacter in stool and determination of significance by culture, enzyme immunoassay, and PCR in developing countries.
        J Clin Microbiol. 2014; 52: 1074-1080
        • Wistrom J.
        • Jertborn M.
        • Ekwall E.
        • et al.
        Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group.
        Ann Intern Med. 1992; 117: 202-208
        • American Academy of Pediatrics
        Shigella infections.
        in: Pickering L.K. Baker C.J. Kimberlin D.W. Red book: 2012 report of the Committee on Infectious Diseases. 29th edition. American Academy of Pediatrics, Elk Grove Village (IL)2012: 645-647
        • Benenson S.
        • Raveh D.
        • Schlesinger Y.
        • et al.
        The risk of vascular infection in adult patients with nontyphi Salmonella bacteremia.
        Am J Med. 2001; 110: 60-63
        • Helms M.
        • Simonsen J.
        • Molbak K.
        Quinolone resistance is associated with increased risk of invasive illness or death during infection with Salmonella serotype Typhimurium.
        J Infect Dis. 2004; 190: 1652-1654
        • Saphra I.
        • Winter J.W.
        Clinical manifestations of salmonellosis in man; an evaluation of 7779 human infections identified at the New York Salmonella Center.
        N Engl J Med. 1957; 256: 1128-1134
        • Sjolund-Karlsson M.
        • Howie R.
        • Krueger A.
        • et al.
        CTX-M-producing non-Typhi Salmonella spp. isolated from humans, United States.
        Emerg Infect Dis. 2011; 17: 97-99
        • Rowe B.
        • Ward L.R.
        • Threlfall E.J.
        Multidrug-resistant Salmonella typhi: a worldwide epidemic.
        Clin Infect Dis. 1997; 24: S106-S109
        • Humphries R.M.
        • Fang F.C.
        • Aarestrup F.M.
        • et al.
        In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards.
        Clin Infect Dis. 2012; 55: 1107-1113
        • Girgis N.I.
        • Butler T.
        • Frenck R.W.
        • et al.
        Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance.
        Antimicrob Agents Chemother. 1999; 43: 1441-1444
        • Frenck Jr., R.W.
        • Mansour A.
        • Nakhla I.
        • et al.
        Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents.
        Clin Infect Dis. 2004; 38: 951-957
        • Sjolund-Karlsson M.
        • Howie R.L.
        • Crump J.A.
        • et al.
        Fluoroquinolone susceptibility testing of Salmonella enterica: detection of acquired resistance and selection of zone diameter breakpoints for levofloxacin and ofloxacin.
        J Clin Microbiol. 2014; 52: 877-884
        • Clinical and Laboratory Standards Institute
        Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement. M100 S25.
        Clinical and Laboratory Standards Institute, Wayne (PA)2015
        • Robicsek A.
        • Strahilevitz J.
        • Jacoby G.A.
        • et al.
        Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase.
        Nat Med. 2006; 12: 83-88
        • Deak E.
        • Hindler J.A.
        • Skov R.
        • et al.
        Performance of Etest and disk diffusion for the detection of ciprofloxacin and levofloxacin resistance in Salmonella.
        J Clin Microbiol. 2015; 53: 298-301
        • Butler T.
        • Sridhar C.B.
        • Daga M.K.
        • et al.
        Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India.
        J Antimicrob Chemother. 1999; 44: 243-250
        • Woodford N.
        • Wareham D.W.
        • Guerra B.
        • et al.
        Carbapenemase-producing Enterobacteriaceae and non-Enterobacteriaceae from animals and the environment: an emerging public health risk of our own making?.
        J Antimicrob Chemother. 2014; 69: 287-291
        • Christopher P.R.
        • David K.V.
        • John S.M.
        • et al.
        Antibiotic therapy for Shigella dysentery.
        Cochrane Database Syst Rev. 2010; (CD006784)
        • Haltalin K.C.
        • Nelson J.D.
        • Ring R.
        • et al.
        Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo.
        J Pediatr. 1967; 70: 970-981
        • Basualdo W.
        • Arbo A.
        Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children.
        Pediatr Infect Dis J. 2003; 22: 374-377
        • Jain S.K.
        • Gupta A.
        • Glanz B.
        • et al.
        Antimicrobial-resistant Shigella sonnei: limited antimicrobial treatment options for children and challenges of interpreting in vitro azithromycin susceptibility.
        Pediatr Infect Dis J. 2005; 24: 494-497
        • Howie R.L.
        • Folster J.P.
        • Bowen A.
        • et al.
        Reduced azithromycin susceptibility in Shigella sonnei, United States.
        Microb Drug Resist. 2010; 16: 245-248
        • Sjolund-Karlsson M.
        • Bowen A.
        • Reporter R.
        • et al.
        Outbreak of infections caused by Shigella sonnei with reduced susceptibility to azithromycin in the United States.
        Antimicrob Agents Chemother. 2013; 57: 1559-1560
        • Gaudreau C.
        • Barkati S.
        • Leduc J.M.
        • et al.
        Shigella spp. with reduced azithromycin susceptibility, Quebec, Canada, 2012-2013.
        Emerg Infect Dis. 2014; 20: 854-856
        • Heiman K.E.
        • Karlsson M.
        • Grass J.
        • et al.
        Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men - United States, 2002-2013.
        MMWR. 2014; 63: 132-133
        • Mandal J.
        • Sangeetha V.
        • Ganesan V.
        • et al.
        Third-generation cephalosporin-resistant Vibrio cholerae, India.
        Emerg Infect Dis. 2012; 18: 1326-1328
        • Ismail H.
        • Smith A.M.
        • Tau N.P.
        • et al.
        Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa. Cholera outbreak in South Africa, 2008-2009: laboratory analysis of Vibrio cholerae O1 strains.
        J Infect Dis. 2013; 208: S39-S45
        • Saha D.
        • Karim M.M.
        • Khan W.A.
        • et al.
        Single-dose azithromycin for the treatment of cholera in adults.
        N Engl J Med. 2006; 354: 2452-2462
        • Sjolund-Karlsson M.
        • Reimer A.
        • Folster J.P.
        • et al.
        Drug-resistance mechanisms in Vibrio cholerae O1 outbreak strain, Haiti, 2010.
        Emerg Infect Dis. 2011; 17: 2151-2154
      5. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline - third edition. CLSI document M45–A3. Wayne (PA): Clinical and Laboratory Standards Institute, in press.

        • Walsh T.R.
        • Weeks J.
        • Livermore D.M.
        • et al.
        Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study.
        Lancet Infect Dis. 2011; 11: 355-362
        • Rossolini G.M.
        • Walsh T.
        • Amicosante G.
        The Aeromonas metallo-beta-lactamases: genetics, enzymology, and contribution to drug resistance.
        Microb Drug Resist. 1996; 2: 245-252
        • Wu C.J.
        • Chen P.L.
        • Wu J.J.
        • et al.
        Distribution and phenotypic and genotypic detection of a metallo-β-lactamase, CphA, among bacteraemic Aeromonas isolates.
        J Med Microbiol. 2012; 61: 712-719
        • Liu Y.M.
        • Chen Y.S.
        • Toh H.S.
        • et al.
        In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
        Int J Antimicrob Agents. 2012; 40: S11-S17
        • Igbinosa I.H.
        • Okoh A.I.
        Antibiotic susceptibility profile of Aeromonas species isolated from wastewater treatment plant.
        ScientificWorldJournal. 2012; 2012: 764563
        • Kunishima H.
        • Chiba J.
        • Saito M.
        • et al.
        Antimicrobial susceptibilities of Clostridium difficile isolated in Japan.
        J Infect Chemother. 2013; 19: 360-362
        • Peláez T.
        • Cercenado E.
        • Alcalá L.
        • et al.
        Metronidazole resistance in Clostridium difficile is heterogeneous.
        J Clin Microbiol. 2008; 46: 3028-3032
        • Leeds J.A.
        • Sachdeva M.
        • Mullin S.
        • et al.
        In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
        J Antimicrob Chemother. 2013; 69: 41-44
        • Labbé A.C.
        • Poirier L.
        • Maccannell D.
        • et al.
        Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.
        Antimicrob Agents Chemother. 2008; 52: 3180-3187
        • Clinical and Laboratory Standards Institute
        Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. CLSI document M100–S23.
        Clinical and Laboratory Standards Institute, Wayne (PA)2013
        • Chen X.
        • Chen Y.
        • Yang Q.
        • et al.
        Plesiomonas shigelloides infection in Southeast China.
        PLoS One. 2013; 8: e77877
        • Zheng H.
        • Sun Y.
        • Lin S.
        • et al.
        Yersinia enterocolitica infection in diarrheal patients.
        Eur J Clin Microbiol Infect Dis. 2008; 27: 741-752